SIGA Technologies, Inc.

NasdaqGM SIGA

SIGA Technologies, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD 104.57 M

SIGA Technologies, Inc. EBIT is USD 104.57 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 1,238.74% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

SIGA Technologies, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -9.18 M, a -106.64% change year over year.
SIGA Technologies, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 138.40 M, a 532.80% change year over year.
SIGA Technologies, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 21.87 M, a -56.73% change year over year.
SIGA Technologies, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 50.55 M, a 1,785.06% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqGM: SIGA

SIGA Technologies, Inc.

CEO	Dr. Diem Nguyen M.B.A., Ph.D.
IPO Date	Sept. 10, 1997
Location	United States
Headquarters	31 East 62nd Street
Employees	45
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

Key trends

Past 5 years